Skip to main content

Chronic Prostatitis

0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Dr. Reddy's Laboratories
1 program
Levofloxacin 500N/A1 trial
Active Trials
NCT02711943Completed500Est. Mar 2014
Hua Medicine
Hua MedicineChina - Shanghai
1 program
TUDPN/A1 trial
Active Trials
NCT04128280Unknown180Est. Dec 2021
Bristol Myers Squibb
1 program
ThalidomidePHASE_21 trial
Active Trials
NCT00301405Terminated9Est. Nov 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bristol Myers SquibbThalidomide
Hua MedicineTUDP
Dr. Reddy's LaboratoriesLevofloxacin 500

Clinical Trials (3)

Total enrollment: 689 patients across 3 trials

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

Start: Mar 2006Est. completion: Nov 20069 patients
Phase 2Terminated

Multi-center Clinical Observation of a New Treatment Method Based on the Pathogenesis of Obstructive Prostatitis

Start: Jan 2020Est. completion: Dec 2021180 patients
N/AUnknown

Non Interventional Study of Levofloxacin in Chronic Prostatitis

Start: Jul 2013Est. completion: Mar 2014500 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.